Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker (NYSE:SYK) announced the launch of its EasyFuse™ Dynamic Compression System for high-demand foot and ankle applications.

Stryker Launches EasyFuse™ Dynamic Compression System for High-Demand Foot and Ankle Applications

Stryker is a Dividend Champion with 28 consecutive years of dividend growth. Shares currently yield 1.20%. Stryker is a leader in the innovative med-tech sector that helps to advance healthcare solutions across a variety of ailments.

Stryker: Innovation And Acquisition

Amazon

Home Depot

Target

Walmart

5 Reasons Why Today's Market Turmoil Shouldn't Shake You

Stryker (NYSE: SYK) announced yesterday that the board of directors approved leadership and committee assignment changes. These are the details.

Stryker (SYK) Announces Board Leadership Changes

Kalamazoo, May 05, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Jason Beach will be appointed Vice President, Investor Relations and report to Glenn Boehnlein, the company's Chief Financial Officer, effective July 1, 2022. Preston Wells, Vice President, Investor Relations will be appointed Vice President, Group Chief Financial Officer for Stryker's Orthopaedics and Spine businesses. Mr. Beach will work closely with Mr. Boehnlein and Mr. Wells to ensure a smooth transition.

Stryker announces new Investor Relations leader

Kalamazoo, May 05, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced that on May 4, 2022, the company's board of directors approved board leadership and committee assignment changes, naming Sherilyn S. McCoy to replace Allan C. Golston as Lead Independent Director, and Mary K. Brainerd to replace Ms. McCoy as Chair of the Governance and Nominating Committee.

Stryker announces board changes following Annual Meeting of Shareholders

While the company's management expects its full-year sales to rise at the higher end of its guided range of 6% to 8%, it expects its adjusted EPS to be toward the lower end of the guided range of $9.60 to $10.00.

Will Stryker Stock See Higher Levels?

InSpace implant demonstrated to be a viable option for patients with massive irreparable rotator cuff tears.* KALAMAZOO, Mich.

Stryker's InSpace subacromial balloon spacer two-year, Level 1 randomized controlled clinical study published in the Journal of Bone and Joint Surgery

Kalamazoo, May 02, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2022 Health Care Conference on Wednesday, May 11, 2022.

Stryker to participate in the Bank of America Securities 2022 Health Care Conference

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.

Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

Stryker Corp (NYSE:SYK ) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Kevin Lobo - Chairman, CEO & President Preston Wells - VP, IR Glenn Boehnlein - VP & CFO Conference Call Participants Vijay Kumar - Evercore ISI Matthew Miksic - Crédit Suisse Robert Marcus - JPMorgan Chase & Co. Jason Wittes - Loop Capital Markets Danielle Antalffy - SVB Leerink Andrew Stafford - Piper Sandler & Co. David Saxon - Needham & Company Ryan Zimmerman - BTIG Andrew Ranieri - Morgan Stanley Richard Newitter - Truist Joshua Jennings - Cowen and Company Joanne Wuensch - Citigroup Lawrence Biegelsen - Wells Fargo Securities Philip Chickering - Deutsche Bank Operator Welcome to the First Quarter 2022 Stryker's Earnings Conference Call. My name is Brika, and I'll be your operator for today.

Stryker Corp (SYK) CEO Kevin Lobo on Q1 2022 Results - Earnings Call Transcript

Kalamazoo, Michigan, April 28, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2022:

Stryker reports first quarter 2022 operating results

We think that Stryker Corp. stock (NYSE: SYK) currently is a better pick compared to its industry peer, Abbott stock (NYSE: ABT), despite it being the more expensive of the two, trading at 6.1x trailing revenues compared to 5.1x for Abbott.

This Medical Devices Company Is A Better Pick Over Abbott Stock

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stryker (SYK) Reports Next Week: What Awaits?

Intuitive Surgical

Johnson & Johnson

Stryker, Johnson & Johnson, and Intuitive Surgical can be counted on to be steady performers in your portfolio.

The Safest Healthcare Stocks in the World

We think that Stryker Corp. stock currently is a better pick compared to its industry peer, Medtronic stock, despite it being the more expensive of the two, trading at 5.7x trailing revenues compared to 4.7x for Medtronic. Even if we were to look at the P/EBIT ratio, SYK stock appears to be more.

This Medical Devices Company Is Likely To Offer Better Returns Over Medtronic Stock

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) on behalf of Stryker stockholders. Our investigation concerns whether Stryker has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Stryker is a medical technology company that operates through two segm

STRYKER ALERT: Bragar Eagel & Squire, P.C. is Investigating Stryker Corporation on Behalf of Stryker Stockholders and Encourages Investors to Contact the Firm

Perhaps one of the most interesting targets of short sellers recently, SYK stock now has a bearish thesis for investors to consider today. The post Why Is Stryker (SYK) Stock in the Spotlight Today?

Why Is Stryker (SYK) Stock in the Spotlight Today?

Shares of Stryker Corporation (NYSE: SYK) have recovered 8.0% in about a month – an uptick that investors should use to get out of the stock, suggests Spruce Point in its recent report. Spruce Point sees downside to $67 a share Spruce Point has a “strong sell opinion” on Stryker Corporation.

Short seller: Stryker Corporation shares could crash ‘up to' 75%

ABIOMED

Edwards Lifesciences

Medtronic

Thermo Fisher Scientific

With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks. The post 7 Medical Device Stocks to Buy as Covid-19 Fears Fade appeared first on InvestorPlace.

7 Medical Device Stocks to Buy as Covid-19 Fears Fade

NuVasive

Orthofix International

Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.

Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus

Kalamazoo, Michigan, March 30, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host a conference call on Thursday, April 28, 2022 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended March 31, 2022 and provide an operational update.Final operating results for the quarter ended March 31, 2022 will be released at 4:05 p.m. that day.

Stryker to host conference call on April 28, 2022

Tractor Supply

Ulta Beauty

These three stocks from diverse industries make great investments during a market correction.

3 Top Stocks to Buy In a Market Pullback

Stryker is a well-established medical devices stock with appealing growth prospects.

News for Stryker Stock (SYK)